MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. SKA-B
5. PBA
6. CCH:LN
7. META
8. CCHGY
9. PRY:IM
10. PRYMY

Go back to MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders

Sarepta Therapeutics (SRPT) Data 'Positive but Some Questions Remain' - Mizuho

May 3, 2021 1:43 PM EDT

Mizuho Securities analyst Difei Yang reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company presented new data from its next-generation exon skipping PPMO at the 30mg dose.

Yang commented, "The data was in line with our "base case"... More